Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian ParneyKatherine Peters, Vinay K. Puduvalli, John Ragsdale, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, Anita Engh

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

Original languageEnglish (US)
Pages (from-to)1331-1345
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Glioma
Histology
Central Nervous System
Guidelines
Neoplasms
Population
Therapeutics
Randomized Controlled Trials
Clinical Trials
Phenotype
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., ... Engh, A. (2017). Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(11), 1331-1345. https://doi.org/10.6004/jnccn.2017.0166

Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines. / Nabors, Louis Burt; Portnow, Jana; Ammirati, Mario; Baehring, Joachim; Brem, Henry; Butowski, Nicholas; Fenstermaker, Robert A.; Forsyth, Peter; Hattangadi-Gluth, Jona; Holdhoff, Matthias; Howard, Steven; Junck, Larry; Kaley, Thomas; Kumthekar, Priya; Loeffler, Jay S.; Moots, Paul L.; Mrugala, Maciej M.; Nagpal, Seema; Pandey, Manjari; Parney, Ian; Peters, Katherine; Puduvalli, Vinay K.; Ragsdale, John; Rockhill, Jason; Rogers, Lisa; Rusthoven, Chad; Shonka, Nicole; Shrieve, Dennis C.; Sills, Allen K.; Swinnen, Lode J.; Tsien, Christina; Weiss, Stephanie; Wen, Patrick Yung; Willmarth, Nicole; Bergman, Mary Anne; Engh, Anita.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 11, 01.11.2017, p. 1331-1345.

Research output: Contribution to journalArticle

Nabors, LB, Portnow, J, Ammirati, M, Baehring, J, Brem, H, Butowski, N, Fenstermaker, RA, Forsyth, P, Hattangadi-Gluth, J, Holdhoff, M, Howard, S, Junck, L, Kaley, T, Kumthekar, P, Loeffler, JS, Moots, PL, Mrugala, MM, Nagpal, S, Pandey, M, Parney, I, Peters, K, Puduvalli, VK, Ragsdale, J, Rockhill, J, Rogers, L, Rusthoven, C, Shonka, N, Shrieve, DC, Sills, AK, Swinnen, LJ, Tsien, C, Weiss, S, Wen, PY, Willmarth, N, Bergman, MA & Engh, A 2017, 'Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 11, pp. 1331-1345. https://doi.org/10.6004/jnccn.2017.0166
Nabors, Louis Burt ; Portnow, Jana ; Ammirati, Mario ; Baehring, Joachim ; Brem, Henry ; Butowski, Nicholas ; Fenstermaker, Robert A. ; Forsyth, Peter ; Hattangadi-Gluth, Jona ; Holdhoff, Matthias ; Howard, Steven ; Junck, Larry ; Kaley, Thomas ; Kumthekar, Priya ; Loeffler, Jay S. ; Moots, Paul L. ; Mrugala, Maciej M. ; Nagpal, Seema ; Pandey, Manjari ; Parney, Ian ; Peters, Katherine ; Puduvalli, Vinay K. ; Ragsdale, John ; Rockhill, Jason ; Rogers, Lisa ; Rusthoven, Chad ; Shonka, Nicole ; Shrieve, Dennis C. ; Sills, Allen K. ; Swinnen, Lode J. ; Tsien, Christina ; Weiss, Stephanie ; Wen, Patrick Yung ; Willmarth, Nicole ; Bergman, Mary Anne ; Engh, Anita. / Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 11. pp. 1331-1345.
@article{2b52072e5afb41d6b4612387ab7dbe3a,
title = "Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines",
abstract = "For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.",
author = "Nabors, {Louis Burt} and Jana Portnow and Mario Ammirati and Joachim Baehring and Henry Brem and Nicholas Butowski and Fenstermaker, {Robert A.} and Peter Forsyth and Jona Hattangadi-Gluth and Matthias Holdhoff and Steven Howard and Larry Junck and Thomas Kaley and Priya Kumthekar and Loeffler, {Jay S.} and Moots, {Paul L.} and Mrugala, {Maciej M.} and Seema Nagpal and Manjari Pandey and Ian Parney and Katherine Peters and Puduvalli, {Vinay K.} and John Ragsdale and Jason Rockhill and Lisa Rogers and Chad Rusthoven and Nicole Shonka and Shrieve, {Dennis C.} and Sills, {Allen K.} and Swinnen, {Lode J.} and Christina Tsien and Stephanie Weiss and Wen, {Patrick Yung} and Nicole Willmarth and Bergman, {Mary Anne} and Anita Engh",
year = "2017",
month = "11",
day = "1",
doi = "10.6004/jnccn.2017.0166",
language = "English (US)",
volume = "15",
pages = "1331--1345",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines

AU - Nabors, Louis Burt

AU - Portnow, Jana

AU - Ammirati, Mario

AU - Baehring, Joachim

AU - Brem, Henry

AU - Butowski, Nicholas

AU - Fenstermaker, Robert A.

AU - Forsyth, Peter

AU - Hattangadi-Gluth, Jona

AU - Holdhoff, Matthias

AU - Howard, Steven

AU - Junck, Larry

AU - Kaley, Thomas

AU - Kumthekar, Priya

AU - Loeffler, Jay S.

AU - Moots, Paul L.

AU - Mrugala, Maciej M.

AU - Nagpal, Seema

AU - Pandey, Manjari

AU - Parney, Ian

AU - Peters, Katherine

AU - Puduvalli, Vinay K.

AU - Ragsdale, John

AU - Rockhill, Jason

AU - Rogers, Lisa

AU - Rusthoven, Chad

AU - Shonka, Nicole

AU - Shrieve, Dennis C.

AU - Sills, Allen K.

AU - Swinnen, Lode J.

AU - Tsien, Christina

AU - Weiss, Stephanie

AU - Wen, Patrick Yung

AU - Willmarth, Nicole

AU - Bergman, Mary Anne

AU - Engh, Anita

PY - 2017/11/1

Y1 - 2017/11/1

N2 - For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

AB - For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85033793575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033793575&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0166

DO - 10.6004/jnccn.2017.0166

M3 - Article

C2 - 29118226

AN - SCOPUS:85033793575

VL - 15

SP - 1331

EP - 1345

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 11

ER -